{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:20:32Z","timestamp":1780323632544,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Long-acting injectable depot buprenorphine may increase access to opioid agonist treatment (OAT) for patients with opioid use disorder in different treatment phases. The aim of this study was to explore the experiences of depot buprenorphine among Swedish patients with ongoing substance use and multiple psychiatric comorbidities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Semi-structured qualitative interviews were conducted with OAT patients with experience of depot buprenorphine. Recruitment took place at two OAT clinics with a harm reduction focus, specializing in the treatment of patients with ongoing substance use and multiple comorbidities. Nineteen participants were included, 12 men and seven women, with a mean age of 41 years (range 24\u201356 years), and a mean of 21 years (5\u201335 years) of experience with illicit substance use. All participants had ongoing substance use and psychiatric comorbidities such as ADHD, anxiety, mood, psychotic and eating disorders. Interviews were transcribed verbatim. Thematic content analysis was conducted both manually and using qualitative data analysis software.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Participants reported social benefits and positive changes in self-perception and identity. In particular, depot buprenorphine contributed to a realization that it was possible to make life changes and engage in activities not related to substance use. Another positive aspect that emerged from the interviews was a noticeable relief from perceived pressure to divert OAT medication, while some expressed the lack of income from diverted oral\/sublingual OAT medication as a negative, but still acceptable, consequence of the depot buprenorphine. Many participants considered that the information provided prior to starting depot buprenorphine was insufficient. Also, not all patients found depot buprenorphine suitable, and those who experienced coercion exhibited particularly negative attitudes towards the medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>OAT patients with ongoing substance use and multiple psychiatric comorbidities reported clear benefits of depot buprenorphine, including changes in self-perception which has been theorized to play an important role in recovery. Clinicians should consider the specific information needs of this population and the extensive diversion of traditional OAT medications in this population to improve the treatment experience and outcomes. Overall, depot buprenorphine is a valuable treatment option for a population in need of harm reduction and may also contribute to psychological changes that may facilitate recovery in those with the greatest need.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00984-1","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T15:02:06Z","timestamp":1711378926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study"],"prefix":"10.1186","volume":"21","author":[{"given":"Bj\u00f6rn","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Monwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Johansson","family":"Capusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"984_CR1","doi-asserted-by":"crossref","unstructured":"Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178:764\u2013773.","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"984_CR2","doi-asserted-by":"crossref","unstructured":"Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778\u2013790.","DOI":"10.2139\/ssrn.3228895"},{"key":"984_CR3","doi-asserted-by":"crossref","unstructured":"Heidbreder C, Fudala PJ, Greenwald MK. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug Alcohol Depend Rep. 2023;6:100133.","DOI":"10.1016\/j.dadr.2023.100133"},{"key":"984_CR4","doi-asserted-by":"crossref","unstructured":"Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416\u20131426.","DOI":"10.1111\/add.14636"},{"key":"984_CR5","doi-asserted-by":"crossref","unstructured":"Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, et al. Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: A randomized clinical trial. JAMA Netw Open. 2021;4(5):e219041.","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"key":"984_CR6","doi-asserted-by":"crossref","unstructured":"Barnett A, Savic M, Lintzeris N, Bathish R, Arunogiri S, Dunlop AJ, et al. Tracing the affordances of long-acting injectable depot buprenorphine: a qualitative study of patients\u2019 experiences in Australia. Drug Alcohol Depend. 2021;227:108959.","DOI":"10.1016\/j.drugalcdep.2021.108959"},{"key":"984_CR7","doi-asserted-by":"crossref","unstructured":"Johnson B, Flensburg OL, Capusan AJ. Patient perspectives on depot buprenorphine treatment for opioid addiction: a qualitative interview study. Subst Abuse Treat Prev Policy. 2022;17:40.","DOI":"10.1186\/s13011-022-00474-2"},{"key":"984_CR8","doi-asserted-by":"crossref","unstructured":"Treloar C, Lancaster K, Gendera S, Rhodes T, Shahbazi J, Byrne M, et al. Can a new formulation of opiate agonist treatment alter stigma? Place, time and things in the experience of extended-release buprenorphine depot. Int J Drug Policy. 2022;107:103788.","DOI":"10.1016\/j.drugpo.2022.103788"},{"key":"984_CR9","doi-asserted-by":"crossref","unstructured":"Clay S, Treloar C, Degenhardt L, Grebely J, Christmas M, Gough C, et al. \u201cI just thought that was the best thing for me to do at this point\u201d: Exploring patient experiences with depot buprenorphine and their motivations to discontinue. Int J Drug Policy. 2023;115:104002.","DOI":"10.1016\/j.drugpo.2023.104002"},{"key":"984_CR10","doi-asserted-by":"crossref","unstructured":"Bartoszko A. Polluting pharmaceutical atmospheres: compulsion, resistance, and symbolism of buprenorphine in Norway. Nord Stud Alcohol Drugs. 2019;36(3):267\u2013285.","DOI":"10.1177\/1455072518814313"},{"key":"984_CR11","doi-asserted-by":"crossref","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtala J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686\u2013693.","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"984_CR12","doi-asserted-by":"crossref","unstructured":"Hudgins A, Uzwiak B, Pizzicato L, Viner K. Barriers to effective care: specialty drug treatment in Philadelphia. J Subst Abuse Treat. 2017;131:108639.","DOI":"10.1016\/j.jsat.2021.108639"},{"key":"984_CR13","doi-asserted-by":"crossref","unstructured":"Aronowitz SV, Hudgins A. Problematizing \u201cpatient stability\u201d in opioid use disorder care: Flexible definitions, (in) flexible treatment. Int J Drug Policy. 2022;108:103804.","DOI":"10.1016\/j.drugpo.2022.103804"},{"key":"984_CR14","unstructured":"Socialstyrelsens f\u00f6reskrifter och allm\u00e4nna r\u00e5d om l\u00e4kemedelsassisterad behandling vid opioidberoende (HSLF-FS 2016:1). 2016. Stockholm: Socialstyrelsen."},{"key":"984_CR15","unstructured":"Socialstyrelsen. Nationella riktlinjer f\u00f6r v\u00e5rd och st\u00f6d vid missbruk och beroende. 2019. Stockholm: Socialstyrelsen."},{"key":"984_CR16","unstructured":"Drug Commission of Inquiry. We can do better! Knowledge-based drugs policy focused on life and health. Swedish Government Official Reports SOU 2023;62:2023."},{"key":"984_CR17","doi-asserted-by":"crossref","unstructured":"Gedeon C, Sandell M, Birkemose I, Kakko J, R\u00fanarsd\u00f3ttir V, Simojoki K, et al. Standards for opioid use disorder care: an assessment of Nordic approaches. Nord Stud Alcohol Drugs. 2019;36(3):286\u2013298.","DOI":"10.1177\/1455072518815322"},{"key":"984_CR18","unstructured":"EMCDDA. European drug report 2022: Trends and developments. Luxembourg: Publications Office of the European Union; 2022."},{"key":"984_CR19","doi-asserted-by":"crossref","unstructured":"Andersson L, H\u00e5kansson A, Krantz P, Johnson B. Investigating opioid-related fatalities in southern Sweden: contact with care-providing authorities and comparison of substances. Harm Reduct J. 2020;17:5.","DOI":"10.1186\/s12954-019-0354-y"},{"key":"984_CR20","doi-asserted-by":"crossref","unstructured":"Andersson L, Johnson B. Patient choice as a means of empowerment in opioid substitution treatment: a case from Sweden. Drugs: Educ Prev Policy. 2020;27(2):105\u2013117.","DOI":"10.1080\/09687637.2019.1591342"},{"key":"984_CR21","doi-asserted-by":"crossref","unstructured":"Johnson B, Richert T. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors. Int J Drug Policy. 2015;26(2):183\u2013190.","DOI":"10.1016\/j.drugpo.2014.10.003"},{"key":"984_CR22","unstructured":"Socialstyrelsen. Nationella riktlinjer f\u00f6r v\u00e5rd och st\u00f6d vid missbruk och beroende [National guidelines for care and support in substance abuse and dependence]. Stockholm: Socialstyrelsen; 2019."},{"key":"984_CR23","unstructured":"Socialstyrelsen. L\u00e4kemedelsassisterad behandling vid opioidberoende: Kunskapsst\u00f6d \u2013 i h\u00e4lso- och sjukv\u00e5rd och socialtj\u00e4nst [Medication-assisted treatment for opioid dependence: Knowledge support \u2013 in healthcare and social services]. Stockholm: Socialstyrelsen; 2020."},{"key":"984_CR24","unstructured":"HSLF-FS 2016:1. Socialstyrelsens f\u00f6reskrifter och allm\u00e4nna r\u00e5d om l\u00e4kemedelsassisterad behandling vid opioidberoende [The National Board of Health and Welfare\u2019s regulations and general advice on medicationassisted treatment for opioid dependence]. https:\/\/www.socialstyrelsen.se\/kunskapsstod-och-regler\/regler-ochriktlinjer\/foreskrifter-och-allmanna-rad\/konsoliderade-foreskrifter\/20161-om-lakemedelsassisterad-behandling-vidopioidberoende\/. Accessed 6 Dec 2023."},{"key":"984_CR25","doi-asserted-by":"crossref","unstructured":"Sturges JE, Hanrahan KJ. Comparing telephone and face-to-face qualitative interviewing: a research note.Qual Res. 2004;4(1):107\u2013118.","DOI":"10.1177\/1468794104041110"},{"key":"984_CR26","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","DOI":"10.1191\/1478088706qp063oa"},{"key":"984_CR27","unstructured":"Svensson B. Pundare, jonkare och andra [Speed-freaks, junkies and others]. Stockholm: Carlssons; 2007."},{"key":"984_CR28","doi-asserted-by":"crossref","unstructured":"McIntosh J, McKeganey N. Addicts\u2019 narratives of recovery from drug use: Constructing a non-addict identity. Soc Sci Med. 2000;50(10):1501\u20131510.","DOI":"10.1016\/S0277-9536(99)00409-8"},{"key":"984_CR29","doi-asserted-by":"crossref","unstructured":"Moshier SJ, McHugh RK, Calkins AW, Hearon BA, Rosellini AJ, Weitzman ML, Otto MW. The role of perceived belongingness to a drug subculture among opioid-dependent patients. Psychol Addict Behav. 2012;26(4):812\u2013820.","DOI":"10.1037\/a0029107"},{"key":"984_CR30","doi-asserted-by":"crossref","unstructured":"Dingle GA, Cruwys T, Frings D. Social identities as pathways into and out of addiction. Front Psychol. 2015;6(1795):1\u201312.","DOI":"10.3389\/fpsyg.2015.01795"},{"key":"984_CR31","doi-asserted-by":"crossref","unstructured":"Lalander P. Illegal street economies and drugs: Getting involved, skilled and trying to quit. In: Kolind T, Hunt G, Thon B, editors. The SAGE Handbook of Drug and Alcohol Studies: Social Science Approaches. London: Sage Publications; 2017.","DOI":"10.4135\/9781473921986.n37"},{"key":"984_CR32","doi-asserted-by":"crossref","unstructured":"Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315\u2013326.","DOI":"10.1097\/ADM.0000000000000045"},{"key":"984_CR33","doi-asserted-by":"crossref","unstructured":"Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: The case of Sweden. Harm Reduct J. 2015;12:12.","DOI":"10.1186\/s12954-015-0037-2"},{"key":"984_CR34","doi-asserted-by":"crossref","unstructured":"Bourgois P. The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments. Subst Use Misuse. 1998;33(11):2323\u20132351.","DOI":"10.3109\/10826089809056260"},{"key":"984_CR35","doi-asserted-by":"crossref","unstructured":"Havnes IA, Clausen T, Middelthon AL. \u201cDiversion\u201d of methadone or buprenorphine: \u201cHarm\u201d versus \u201chelping\u201d. Harm Reduct J. 2013;10:24.","DOI":"10.1186\/1477-7517-10-24"},{"key":"984_CR36","doi-asserted-by":"crossref","unstructured":"Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: Patients who regularly sell or share their medication. J Addict Dis. 2015;34(1):1\u201317.","DOI":"10.1080\/10550887.2014.975617"},{"key":"984_CR37","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Sys Rev. 2014;2:CD002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"984_CR38","doi-asserted-by":"crossref","unstructured":"Neale J, Parkin S, Strang J. How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis. Addiction. 2023;118(7):1329\u20131339.","DOI":"10.1111\/add.16171"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00984-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00984-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00984-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T15:03:54Z","timestamp":1711379034000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00984-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00984-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is part of a research project studying the introduction of depot buprenorphine in Sweden, approved by the Swedish Ethical Review Authority (reference no. 2020\u2009\u2212\u200900796).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Andrea J Capusan has received speaker\u2019s fees, and\/or scientific advisory board compensation from Lundbeck, Indivior, Camurus, and DNE Pharma, all outside the scope of the current project.Bj\u00f6rn Johnson has no competing interests to declare.Bodil Monwell has no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}